Effect of comprehensive intervention program on survival of patients with human immunodeficiency virus infection

Archives of Internal Medicine

Volumn 156, Issue 2, 1996, Pages 169-176

  Laraque, Fabienne ^a,c,d   Greene, Alison ^b   Triano Davis, J Warren ^c   Altman, Ronald ^c   Lin Greenberg, Alan ^b  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b JERSEY CITY MEDICAL CENTER   (United States)

^c NEW JERSEY DEPARTMENT OF HEALTH AND SENIOR SERVICES   (United States)

^d NEW YORK DOWNTOWN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PATIENT CARE; PRIORITY JOURNAL; SURVIVAL; T LYMPHOCYTE SUBPOPULATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CD4 LYMPHOCYTE COUNT; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; NEW JERSEY; PROGRAM EVALUATION; RISK; SURVIVAL ANALYSIS;

EID: 0030038936     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.156.2.169     Document Type: Article

References (37)

1. Fauci AS. The human immunodeficiency virus: infectivity and mechanisms of pathogenesis. Science. 1988;239:617-622.
2. Lemp GF, Payne SF, Neal D, Temelso T, Rutherford GW. Survival trends for patients with AIDS. JAMA. 1990;263:402-406.
3. Fischl MA, Richman DD, Grieco MH, et al The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. N Engl J Med. 1987;317:185-191
4. Volberding PA, Lagakos SW, Koch MA, et al. Zidovudine in asymptomatic human immunodeficiency virus infection. N Engl J Med. 1990;322.941-949
5. Lagakos S, Fischl MA, Stein DS, Lim L, Volberding P. Effects of zidovudine therapy in minority and other subpopulations with early HIV infection. JAMA. 1991;266:2709-2712.
6. Vella S, Giuliano M, Pezzotti P, et al. Survival of zidovudine-treated patients with AIDS compared with that of contemporary untreated patients. JAMA 1992; 267:1232-1236
7. + T cell counts greater than 400 per cubic millimeter. N Engl J Med. 1993;329:297-303.
8. Hamilton JD, Hartigan PM, Simberkoff MS, et al. A controlled trial of early versus late treatment with zidovudine in symptomatic human immunodeficiency virus infection. N Engl J Med. 1992;326:437-443.
9. Vella S, Giuliano M, Dally LG, et al. Long-term follow-up of zidovudine therapy in asymptomatic HIV infection: results of a multicenter cohort study. J AIDS. 1993;7:31-38
10. Ragni MV, Kingsley LA, Zhou SJ The effect of antiviral therapy on the natural history of human immunodeficiency virus infection in a cohort of hemophiliacs. J AIDS. 1992;5 120-126.
11. Moore RD, Hidalgo J, Sugland BW, Chaisson RE Zidovudine and the natural history of the acquired immunodeficiency syndrome. N Engl J Med. 1991;324: 1412-1416
12. Graham NMH, Zeger SL, Park LP, et al. The effects on survival of early treatment of human immunodeficiency virus infection. N Engl J Med. 1992;326: 1037-1042.
13. Recommendations for zidovudine: early infection. JAMA. 1990;263:1606-1609.
14. Aboulker J-P, Swart AM. Preliminary analysis of the Concorde Trial. Lancet. 1993;341:889-890.
15. Concorde Coordinating Committee Concorde: MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection. Lancet. 1994;343:871-881.
16. Pape JW, Jean SS Ho JL, Hafner A, Johnson WD Jr. Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infection. Lancet. 1993;342:268-272.
17. Osmond D, Charlebois E, Lang W, Shiboski S, Moss A. Changes in AIDS survival time in two San Francisco cohorts of homosexual men, 1983 to 1993 JAMA. 1994;271:1083-1087.
18. Graham NMH, Zeger SL, Park LP, et al Effect of zidovudine and Pneumocystis carinii pneumonia prophylaxis on progression of HIV-1 infection to AIDS. Lancet 1991,338.265-269
19. Francis DP, Anderson RE, Gorman ME, et al. Targeting AIDS prevention and treatment toward HIV-1-infected persons. JAMA. 1989;262:2572-2576.
20. Jewett JF, Hecht FM Preventive health care for adults with HIV infection. JAMA 1993;269.1144-1153.
21. Dixon RE, Altrnan R, Sensakovic J, Williams N, Saunders S, Davidson R. Identification and Management of Asymptomatic HIV-Infected Persons in New Jersey: A Practical Protocol for New Jersey Clinicians 2nd ed. Lawrenceville, NJ: The Academy of Medicine of New Jersey, Trenton, NJ: New Jersey State Department of Health; 1992.
22. Centers for Disease Control. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Morb Mortal Wkly Rep. 1992;41:1-19.
23. Centers for Disease Control. Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. MMWR Morb Mortal Wkly Rep. 1987; 36(suppl 1):1S-15S.
24. Centers for Disease Control. Human immunodeficiency virus (HIV) infection codes and new codes for Kaposi's sarcoma. MMWR Morb Mortal Wkly Rep 1991;40(RR-9):1-19.
25. SAS Institute Inc. SAS/STAT Version, 6.03 Edition, 1988 Cary, NC: SAS Inc; 1988.
26. Hopewell PC. AIDS and the lung: prevention of lung infections associated with human immunodeficiency virus infection. Thorax. 1989;44:1038-1044.
27. Guenter P, Muurahainen N, Simons G, et al. Relationships among nutritional status, disease progression, and survival in HIV infection. J AIDS. 1993;6: 1130-1138.
28. Semba RD, Graham NMH, Caiaffa WT, Margolick JS, Clement L, Vlahov D. Increased mortality associated with vitamin A deficiency during human immunodeficiency virus type 1 infection. Arch Intern Med 1993;153.2149-2154
29. Tang AM, Graham NMH, Kirby AJ, McCall LD, Willett WC, Saah AJ. Dietary micronutrient intake and risk of progression to acquired immunodeficiency syndrome (AIDS) in human immunodeficiency virus type 1 (HIV-1)-infected homosexual men. Am J Epidemiol. 1993;138:937-951.
30. Coodley GO, Nelson HD, Loveless MO, Folk C. β-Carotene in HIV infection. J AIDS. 1993;6:272-276.
31. Moore RD, Stanton D, Gopalan R, Chaisson RE. Racial differences in the use of drug therapy for HIV disease in an urban community. N Engl J Med. 1994; 330:763-768.
32. Gardner LI, Brundage JF, McNeil JG, et al. Predictors of HIV-1 disease progression in early- and late-stage patients: the U.S. Army Natural History Cohort. J AIDS. 1992;5:782-793.
33. Easterbrook PJ, Emami J, Moyle G, Gazzard BG. Progressive CD4 cell depletion and death in zidovudine-treated patients. J AIDS. 1993;6:927-929
34. Chang H-GH, Morse DL, Noonan C, et al. Survival and mortality patterns of an acquired immunodeficiency (AIDS) cohort in New York State. Am J Epidemiol. 1993;138:341-349.
35. Stein M, Piette J, Mor V, et al. Differences in access to zidovudine (AZT) among symptomatic HIV-infected persons. J Gen Intern Med. 1991;6:35-40.
36. Council on Ethical and Judicial Affairs, American Medical Association. Black-white disparities in health care. JAMA. 1990;263:2344-2346.
37. Nickens HW. The health status of minority populations in the United States. West J Med. 1991;155:27-32.